Wolverine Stack Stack Protocol

Stack Overview — What It Is

The Wolverine Stack — BPC-157 plus TB-500 — is the most-run peptide recovery protocol in the optimization community. Its durable popularity is mechanistic: BPC-157 builds the local vascular supply at an injury site; TB-500 moves the repair cells to it. Two peptides, two non-overlapping mechanisms, one combined repair phenotype. The name comes from the Wolverine character's signature rapid tissue-healing trope, which captures community framing more accurately than the evidence does.

Who this is for: adults with a specific soft-tissue injury (tendinopathy, ligament sprain, muscle tear, post-surgical recovery), people dealing with stubborn joint pain that has plateaued on conventional rehab, and athletes returning from overuse injuries who want to shorten the remodeling timeline. Also widely used off-label for post-operative recovery and chronic GI inflammation (the BPC-157 arm has the best evidence for gut healing).

Who this is NOT for: anyone with active or recent malignancy (both peptides upregulate angiogenesis — the pathway cancer uses to vascularize tumors). Athletes subject to WADA testing (both are banned). People with uncontrolled hypertension or cardiovascular disease without clinician oversight. Pregnant or breastfeeding. Anyone expecting this to replace physical therapy or surgical intervention for a structural injury — the stack accelerates repair, it does not restructure damaged architecture.

Honest framing: no randomized controlled trial has tested this combination in humans. The rationale is individual-compound preclinical evidence plus mechanistic synergy plus approximately 15 years of community use. If you want trial-proven, this is not that. If you want the most evidence-dense off-label peptide recovery stack in community circulation, this is it.

Mechanism of Action — The Compounds and Their Synergy

Why they pair: BPC-157 creates the capillary bed the repair cells need; TB-500 delivers the cells. BPC-157 is local and short-acting (daily or twice-daily dosing); TB-500 is systemic and long-acting (weekly dosing). BPC-157's mechanism dominates early in a repair cycle; TB-500's mechanism dominates mid-to-late remodeling. They are complementary in tissue, timing, and pharmacokinetics.

• Vascular supply first — BPC-157 drives VEGFR2-Akt-eNOS signaling to build capillaries around the injury, delivering oxygen, nutrients, and clearing metabolic waste.
• Cellular delivery second — TB-500's G-actin sequestration regulates the leading-edge cytoskeleton that drives fibroblast, endothelial, and immune cell migration toward the newly vascularized region.
• Complementary half-lives — BPC-157's short half-life gives daily peak local exposure; TB-500's multi-day half-life provides sustained systemic repair signaling. Two dosing cadences, one combined effect.
• Anti-inflammatory convergence — Both reduce pro-inflammatory cytokines via independent pathways, producing additive anti-inflammatory tone without broad immunosuppression.
• No redundant pathway — The mechanistic orthogonality is why the combination outperforms either solo in community reports. You are not double-dosing one pathway; you are covering two.

What the Research Shows

• No human RCT of the combination — As of April 2026, no randomized controlled trial has ever tested the BPC-157 + TB-500 combination in humans.
• BPC-157 preclinical base — Sikiric, Seiwerth, and colleagues have published ~150 papers since 1993 characterizing BPC-157 across gut, musculoskeletal, neurologic, and cardiovascular preclinical models. The pentadecapeptide is one of the best-preclinically-characterized research peptides.
• BPC-157 tendon healing — Staresinic et al., J Orthop Res 2003 (PMID 14554208) — accelerated Achilles tendon transection healing in rat. Krivic et al., J Orthop Res 2006 (PMID 16583442) — promoted tendon-to-bone healing in the Achilles detachment model.
• BPC-157 vascular mechanism — Hsieh et al., Sci Rep 2020 (PMID 33051481) — Src-Caveolin-1-eNOS vasomotor and angiogenesis signaling in isolated vessels.
• BPC-157 MSK systematic review — Vasireddi et al., J Orthop Surg Res 2025 (PMID 40756949) — recent systematic review of BPC-157 in musculoskeletal medicine.
• TB-500 / Thymosin β4 discovery — Low et al., PNAS 1981 (PMID 6940133) — complete amino acid sequence of bovine Tβ4.
• TB-500 cardiac repair — Bock-Marquette et al., Nature 2004 (PMID 15565145) — Tβ4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair.
• TB-500 myocardial progenitor activation — Smart et al., Nature 2011 (PMID 21654746) — Tβ4 activated adult epicardial progenitor cells producing cardiomyocytes in injury models.
• TB-500 corneal repair — Sosne et al., Invest Ophthalmol Vis Sci 2005 — Tβ4 modulates corneal matrix metalloproteinase and polymorphonuclear cell infiltration after alkali injury. Human compassionate-use corneal-injury reports describe benefit.
• TB-500 safety toxicology — Xu et al., Regul Toxicol Pharmacol 2020 (PMID 32768655) — preclinical safety evaluation of BPC-157 for wound healing.
• Human BPC-157 data — Limited. Small Croatian clinical trials in IBD and a handful of case series. No Phase 2/3 registration program.
• Human TB-500 data — Extensive veterinary (equine) use but limited human clinical data outside ophthalmology compassionate use.

Human Data

• Stack combination — None. No RCT, no case series, no published combined protocol data.
• BPC-157 Croatian IBD pilots — Limited small human trials from the Sikiric group (primary publishing center).
• BPC-157 community reports — Extensive anecdotal tissue-repair reports over 15+ years; selection-biased toward responders.
• TB-500 corneal compassionate-use — Small human case series in severe corneal injury.
• TB-500 veterinary base — Much more substantive equine and canine veterinary use and research than human clinical experience; not directly translatable to human therapeutic framing.
• Both compounds — No completed FDA Phase 2/3 registration program. No registrational pathway active as of April 2026.

Dosing from the Literature

Most community users run the Wolverine Stack as a pre-blended 1:1 vial (either 10 mg/10 mg or 5 mg/5 mg). Separate vials are used when non-1:1 ratios or different cadences are preferred.

Standard community protocol — pre-blend: 0.1 mL (10 units) daily SubQ. The 10/10 mg vial delivers 500 µg of each per injection; the 5/5 mg vial delivers 250 µg of each. Choose vial strength rather than scaling volume — 10-unit draws are easier to measure consistently on insulin syringes.

Standard community protocol — separate vials: BPC-157 250–500 µg daily (5–10 units from a 5 mg/mL reconstitution), plus TB-500 2–2.5 mg 2× per week during a 2-week loading phase (40–50 units), then 2 mg 1× per week maintenance. Separate vials give flexibility when more TB-500 is wanted than the 1:1 pre-blend provides during loading.

Technique: 29G–31G half-inch insulin syringe. SubQ at 45° into abdomen (2 inches from navel) or near-injury tissue. Rotate sites. Reconstituted solution: refrigerate at 2–8°C, use within 28 days. Do not freeze.

→ Use the Kalios Peptide Calculator for exact syringe units

Reconstitution & Storage (Sample Schedules)

Two common dosing patterns — pre-blend is simpler (one injection daily); separate vials give more loading-phase flexibility.

Pattern A — Pre-blend 10/10 mg vial, 5 mg/mL each:

Weekly totals: 3.5 mg of each. One 10/10 mg pre-blend vial lasts ~20 days at daily 0.1 mL. For a lower-dose equivalent, use the 5/5 mg pre-blend (250 µg of each per 0.1 mL).

Pattern B — Separate vials with front-loaded TB-500 (weeks 1–2):

Weekly totals: BPC-157 ~1.75 mg, TB-500 4 mg (loading weeks), dropping to 2 mg weekly (maintenance).

• Cycle length — 8–12 weeks on, 4+ weeks off. Two consecutive cycles is the upper end for a single injury.
• Storage — Reconstituted: refrigerated 2–8°C; use within 28 days. Do not freeze.
• Inspection — Discard if cloudy, discolored, or particulate.
• Injection site rotation — Across abdomen quadrants and thighs; more critical here than for weekly-dosed peptides because of daily cadence.

Side Effects & Risks

• BPC-157 — Generally well-tolerated. Occasional mild nausea, dizziness, head pressure. Injection-site soreness. Rare paradoxical fatigue in the first few doses.
• TB-500 — Injection-site tenderness (more common than BPC-157). Occasional flu-like fatigue at loading doses. Rare mild histamine-like flushing.
• Combined — No unique additive side effects beyond the individual components. Head-cold-like symptoms in the first week are commonly reported and typically resolve by week 2.
• Angiogenesis / tumor concern — Both peptides promote angiogenesis. Theoretical concern in active or recent malignancy, and in occult cancer (prostate, colorectal, breast screening should be up to date before running).
• WADA prohibition — Both banned. BPC-157 was added to S0 (non-approved substances) in 2021; TB-500 falls under S2 (peptide hormones, growth factors, related substances, and mimetics).
• Hypersensitivity — Rare; discontinue if systemic allergic symptoms develop.
• Sterile technique — Alcohol-swab vial stopper each time; do not reuse needles. Injection infection is more common than product failure.
• Source quality — Third-party HPLC + mass spec COAs are the minimum bar. Purity failures are more common for TB-500 than BPC-157 because Tβ4 is harder to synthesize cleanly at commodity scale.
• Pregnancy / lactation / active cancer — Contraindicated.
• Red flags to stop — Persistent severe injection-site reaction, new unexplained lumps or swellings, sudden vision changes, chest pain, unexplained GI bleeding. Stop and evaluate.

Bloodwork & Monitoring

• Baseline CMP + CBC — Standard metabolic / hematologic baseline before starting.
• Liver function tests — If running >12 weeks or combining with other compounds.
• hsCRP / ESR — Track systemic inflammation markers objectively.
• Imaging (MRI or ultrasound) — For a specific MSK injury, pre- and post-cycle imaging gives the only objective structural answer. Subjective pain scores are the weakest endpoint.
• Functional testing — Range-of-motion, grip strength (for upper-limb injury), loaded-movement tolerance. Objectify the response.
• Cancer screening (pre-cycle) — Age- and sex-appropriate screening up to date given angiogenesis concern.
• Blood pressure — Baseline; both peptides have vasoactive preclinical effects.

Supportive Nutrition & Adjuncts

Peptide repair biology operates on top of — not in place of — nutritional and mechanical-load foundations. The adjuncts below are higher-leverage for soft-tissue repair than most single-compound peptide choices.

• Hydrolyzed collagen (15 g) + vitamin C (50 mg) — 30–60 minutes pre-rehab. Shaw et al. and follow-on studies have shown acute plasma amino-acid / collagen-fragment availability that supports tendon remodeling during loaded rehab. Strongest non-peptide evidence in the tissue-repair space.
• Protein (1.6–2.2 g/kg) — Foundational substrate for all tissue repair.
• Creatine monohydrate (3–5 g) — Training capacity and recovery support during active rehab.
• Vitamin C (500–1,000 mg) — Collagen hydroxylation cofactor.
• Vitamin D (target 40–60 ng/mL) — Soft-tissue and bone repair support.
• Zinc (15–25 mg) with copper (1–2 mg) — Wound-healing cofactors.
• Omega-3 (2–3 g EPA/DHA) — Inflammation resolution.
• Magnesium (300–400 mg) — Muscle and connective-tissue recovery.
• Sleep (7–9 hours) — The single most underrated recovery input.
• Structured rehab / PT — The mechanical-load stimulus the peptides amplify. Without load, peptide-driven tissue remodeling under-delivers.
• Things to avoid during a cycle — Chronic alcohol (directly antagonizes repair biology), chronic NSAIDs (impair tendon/muscle adaptation to load), chronic sleep deprivation, overtraining without recovery programming.

Cycle Structure & What to Expect — Timeline

• Loading phase (weeks 1–6) — BPC-157 daily or twice daily; TB-500 twice weekly for first 2 weeks, then once weekly. Most of the acceleration reportedly happens here.
• Maintenance phase (weeks 7–12) — BPC-157 once daily; TB-500 once weekly. Continued remodeling with lower injection burden.
• Washout (weeks 13–16, minimum 4 weeks) — Stop both. Avoids theoretical receptor desensitization; provides a clean baseline for assessing residual benefit; reduces cumulative peptide exposure.
• Re-cycle — If injury recovery incomplete after one cycle, a second 8–12 week cycle after the 4-week washout. Most users don't need more than two consecutive cycles for a single injury.
• Week 1 — Injections become routine. Most users feel nothing systemic. Some report mild localized warmth at injection sites near injury. No objective changes yet.
• Week 2–3 — First subjective changes in responders: reduced morning stiffness, less pain-with-load, slightly better ROM. Placebo and natural-healing confounders strongest here.
• Week 4–6 — Primary response window. Responders usually know by now. Objective improvements: reduced swelling, earlier comfort during loaded activity, faster session-to-session recovery.
• Week 7–9 — If responding, plateau begins. Continued but decelerating improvement. Non-response by this point rarely reverses.
• Week 10–12 — Completion phase. Maintenance dose sustains gains.
• Washout persistence — Benefits typically persist because both peptides drive actual tissue remodeling rather than symptom-masking.
• Timing relative to PT/rehab — Best results reported when protocol overlaps structured rehab. Some inject BPC-157 30–60 min before loaded rehab for peak local vascular availability (mechanistic rationale, not trial-proven).
• Non-responder diagnostic checklist — Correct diagnosis? Peptide-responsive injury? Product quality (COA)? Injection technique (SubQ, not IM or intradermal)? Underlying biology (smoker, uncontrolled diabetes, chronic steroid user, ongoing exposure)?

Practical User Notes

• Inject near the injury for local effect — BPC-157's short half-life means local injection delivers more drug to the target tissue. Shoulder → deltoid. Knee → peri-patellar fat pad. Achilles → calf SubQ adjacent to tendon.
• Twice-daily BPC-157 beats once-daily — Short half-life justifies AM/PM split dosing. Same total dose, better pharmacokinetic coverage.
• TB-500 doesn't care where you inject — Long half-life, systemic distribution. Abdomen is fine.
• Pre-blended vs separate vials — Pre-blended is simpler for most people. Separate vials win if you want non-1:1 ratios or different injection sites per peptide.
• Source discipline — Third-party HPLC + mass spec COA is the minimum bar. No COA, no purchase. Purity failures more common in TB-500 than BPC-157 because Tβ4 is harder to synthesize cleanly.
• Sterile technique — Alcohol-swab vial stopper every time; wash hands; don't reuse needles. Infection ruins a cycle faster than any product quality issue.
• Pair with rehab, not instead of it — The biggest mistake is running peptides while skipping PT. Peptides accelerate mechanical-load response; without load the protocol fails.
• Nutrition, alcohol, sleep — High-protein diet (1.6–2.2 g/kg), avoid chronic alcohol, prioritize sleep. Bigger levers than the peptides.
• Dose timing with training — Some inject BPC-157 30–60 min before loaded rehab for peak vascular availability. Mechanistically coherent; not trial-proven.
• Don't stack everything at once — Start minimal. Add compounds only if baseline insufficient.
• If it's not working, stop — Week 6–8 you should have a clear signal. No signal → something is wrong: diagnosis, product, technique, biology. Don't double-dose to force a response.
• Red flags — Persistent severe injection-site reaction, new unexplained swellings or lumps, sudden vision changes, chest pain, unexplained GI bleeding. Stop and get evaluated.

Substitutions & Alternatives — Commonly Stacked With / Instead Of

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching the Wolverine Stack often also look at these:

Next Steps

Key References

No clinical trial has studied the BPC-157 + TB-500 combination in humans. The references below are for the individual components and mechanistic framework.

1. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PMID: 21548867.
2. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21(6):976-983. PMID: 14554208.
3. Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing. J Orthop Res. 2006;24(5):982-989. PMID: 16583442.
4. Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. PMID: 33051481.
5. Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. PMID: 32768655.
6. Vasireddi N, et al. The current state of BPC-157 in musculoskeletal medicine: a systematic review. J Orthop Surg Res. 2025;20(1). PMID: 40756949.
7. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4. Proc Natl Acad Sci USA. 1981;78(2):1162-1166. PMID: 6940133.
8. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15565145.
9. Smart N, Bollini S, Dubé KN, et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature. 2011;474(7353):640-644. PMID: 21654746.
10. Sosne G, Christopherson PL, Barrett RP, Fridman R. Thymosin-beta 4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury. Invest Ophthalmol Vis Sci. 2005;46(7):2388-2395. PMID: 15980226.
11. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID: 22074294.
12. Crockford D. Development of thymosin beta4 for treatment of patients with ischemic heart disease. Ann N Y Acad Sci. 2007;1112:385-395. PMID: 17947591.
13. FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) — 503A / 503B list. FDA.gov, updated 2025.
14. WADA. 2025 Prohibited List. Section S0 (BPC-157) and S2 (TB-500 / Tβ4). World Anti-Doping Agency, 2025.
15. HHS Office of the Secretary. February 2026 peptide reclassification announcement regarding Category 2 bulk drug substances. Public communications, 2026.

→ Use the Kalios Peptide Calculator to convert your vial + BAC water into syringe units